Keymed Biosciences Inc. (02162.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−21.4x

Market Cap

HKD 23.82B

MomentumView details →

1D Return

−0.99%

YTD Return

+49.20%

RSI (14)

53.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−21.4x

Market Cap

HKD 23.82B

RSI (14)

53.4

MomentumView details →

1D Return

−0.99%

YTD Return

+49.20%

ProfitabilityView details →

Gross Margin

82.11%

Net Margin

29.91%

EBITDA Margin

−49.33%

ROE (TTM)

12.66%

ROA (TTM)

8.94%

Asset Turnover

0.34x

GrowthView details →

Revenue YoY

+314.51%

EPS YoY

+146.51%

FCF YoY

+1.75%

Revenue CAGR 3Y

+91.05%

EPS CAGR 3Y

+5.58%

EBITDA YoY

+28.85%

EarningsView details →

EPS (Actual)

HKD 4.95

EPS Surprise

−6.78%

Beats (12Q)

0/12

Next Q EPS Est

—

Avg Surprise (4Q)

−6.78%

Rev Surprise

0.20%

Capital & dividendView details →

Debt/Equity

0.17x

Current Ratio

4.83x

Quick Ratio

4.55x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.69B

Net Income (TTM)

506.91M

Op. CF (TTM)

−973.60M

Next earningsMar 30, 2027 →

Latest newsMore news →

Kangnuo-B signed an exclusive licensing agreement with Aeira Pte. Ltd. for the registration and commercialization of its self-developed Stapokibart injection (Kangyueda) in 18 countries and regions in Southeast Asia and Central Asia.2d ago

KeyBanc Capital Markets raised its price target on Keysight Technologies to $210 from $195 and maintained an Overweight rating, citing strong demand for AI-related testing solutions.4d ago

Similar companies

天坛生物600161.SH Biocytogen Pharmaceuticals (Beijing) Co., Ltd.02315.HK 特宝生物688278.SH Zai Lab Limited09688.HK Roivant Sciences Ltd.ROIV Incyte CorporationINCY Find similar companies →

Latest newsMore news →

Kangnuo-B signed an exclusive licensing agreement with Aeira Pte. Ltd. for the registration and commercialization of its self-developed Stapokibart injection (Kangyueda) in 18 countries and regions in Southeast Asia and Central Asia.2d ago KeyBanc Capital Markets raised its price target on Keysight Technologies to $210 from $195 and maintained an Overweight rating, citing strong demand for AI-related testing solutions.4d ago